Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYNX-3: Phentolamine Ophthalmic Solution for Decreased Visual Acuity Under Mesopic Conditions Post-Keratorefractive Surgery
NCT07140783Phase 3Recruiting
- Sponsor
- Opus Genetics
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nyctalopia comparing 0.75% Phentolamine Ophthalmic Solution with Placebo (2 arms). Primary endpoint: Mesopic Low Contrast Visual Acuity Improvement at 15 days. Started Sep 2025; status: recruiting.
02
Drugs
phentolamine
03
Conditions
nyctalopia
Beyond the preview
Go deeper on NCT07140783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140783.